Predict your next investment

Asset/Investment Management
cnpic.com.cn

See what CB Insights has to offer

Investments

2

Portfolio Exits

1

About Sinopharm Investment

Sinopharm Investment is a subsidiary of Sinopharm, focusing on the financial services and equity investment in the healthcare industry.

Sinopharm Investment Headquarter Location

Beijing, Beijing,

China

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Sinopharm Investment Investments

2 Investments

Sinopharm Investment has made 2 investments. Their latest investment was in Xishan as part of their Series D on December 12, 2021.

CBI Logo

Sinopharm Investment Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

12/13/2021

Series D

Xishan

$15.75M

Yes

7

6/13/2020

Corporate Minority

Subscribe to see more

$99M

Subscribe to see more

10

Date

12/13/2021

6/13/2020

Round

Series D

Corporate Minority

Company

Xishan

Subscribe to see more

Amount

$15.75M

$99M

New?

Yes

Subscribe to see more

Co-Investors

Sources

7

10

Sinopharm Investment Portfolio Exits

1 Portfolio Exit

Sinopharm Investment has 1 portfolio exit. Their latest portfolio exit was MXB Biotechnologies on September 08, 2021.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

9/8/2021

Corporate Majority - II

1

Date

9/8/2021

Exit

Corporate Majority - II

Companies

Valuation

Acquirer

Sources

1

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.